|Articles|March 9, 2020
Novotech Wins Contract for Komipharm Coronavirus Covid-19 Trial in South Korea
Advertisement
Asia-Pacific biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus - Covid-19. Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Future-Proofing Clinical Trial Supply Chains Against Tariff Risks
2
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
3
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
4
After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
